142 related articles for article (PubMed ID: 4035008)
1. Vasopressin pressor antagonist injected centrally reverses behavioral effects of peripheral injection of vasopressin, but only at doses that reverse increase in blood pressure.
Lebrun C; Le Moal M; Koob GF; Bloom FE
Regul Pept; 1985 Jun; 11(2):173-81. PubMed ID: 4035008
[TBL] [Abstract][Full Text] [Related]
2. Arginine vasopressin and a vasopressin antagonist peptide: opposite effects on extinction of active avoidance in rats.
Koob GF; Le Moal M; Gaffori O; Manning M; Sawyer WH; Rivier J; Bloom FE
Regul Pept; 1981 Jun; 2(3):153-63. PubMed ID: 7255768
[TBL] [Abstract][Full Text] [Related]
3. Central injections of arginine vasopressin prolong extinction of active avoidance.
Koob GF; Dantzer R; Bluthé RM; Lebrun C; Bloom FE; Le Moal M
Peptides; 1986; 7(2):213-8. PubMed ID: 3737445
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of effects of vasopressin (AVP) on inhibitory avoidance by a vasopressin antagonist peptide [dPtyr(Me)AVP].
LeBrun CJ; Rigter H; Martinez JL; Koob GF; Le Moal M; Bloom FE
Life Sci; 1984 Oct; 35(14):1505-12. PubMed ID: 6482669
[TBL] [Abstract][Full Text] [Related]
5. Vasopressin antagonists block peripheral as well as central vasopressin receptors.
De Wied D; Gaffori O; Van Ree JM; De Jong W
Pharmacol Biochem Behav; 1984 Sep; 21(3):393-400. PubMed ID: 6093152
[TBL] [Abstract][Full Text] [Related]
6. Osmotic stress mimics effects of vasopressin on learned behaviour.
Koob GF; Dantzer R; Rodriguez F; Bloom FE; Le Moal M
Nature; 1985 Jun 27-Jul 3; 315(6022):750-2. PubMed ID: 4010780
[TBL] [Abstract][Full Text] [Related]
7. Vascular effects of arginine vasopressin during fluid deprivation in the rat.
Aisenbrey GA; Handelman WA; Arnold P; Manning M; Schrier RW
J Clin Invest; 1981 Apr; 67(4):961-8. PubMed ID: 7204578
[TBL] [Abstract][Full Text] [Related]
8. Prolonged inhibition of pressor response to vasopressin by a potent specific antagonist, [1-(beta-mercapto-beta, beta-cyclopentamethylenepropionic acid) 2-(O-methyl)tyrosine]arginine-vasopressin.
Pang CC; Leighton KM
Can J Physiol Pharmacol; 1981 Sep; 59(9):1008-12. PubMed ID: 6895346
[TBL] [Abstract][Full Text] [Related]
9. Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor?
de Wied D; Elands J; Kovács G
Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1494-8. PubMed ID: 1847526
[TBL] [Abstract][Full Text] [Related]
10. Enhanced pressor responses to ICV vasopressin after pretreatment with oxytocin.
Poulin P; Komulainen A; Takahashi Y; Pittman QJ
Am J Physiol; 1994 Feb; 266(2 Pt 2):R592-8. PubMed ID: 8141420
[TBL] [Abstract][Full Text] [Related]
11. Central target for the behavioural effects of vasopressin neuropeptides.
de Wied D; Gaffori O; van Ree JM; de Jong W
Nature; 1984 Mar 15-21; 308(5956):276-8. PubMed ID: 6322010
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
[TBL] [Abstract][Full Text] [Related]
13. The effect of a vasopressin antagonist on the pressor response to histamine administered centrally.
Gatti PJ; Gertner SB
Neuropharmacology; 1983 Jul; 22(7):895-902. PubMed ID: 6688661
[TBL] [Abstract][Full Text] [Related]
14. Participation of arginine vasopressin-mediated and adrenergic system-mediated mechanisms in the hypertension induced by intracerebroventricular administration of NMDA in freely moving rats.
Maione S; Vitagliano S; Berrino L; Lampa E; Rossi F
Neuropharmacology; 1992 Apr; 31(4):403-7. PubMed ID: 1355901
[TBL] [Abstract][Full Text] [Related]
15. Central vasopressin raises arterial pressure by sympathetic activation and vasopressin release.
Janiak P; Kasson BG; Brody MJ
Hypertension; 1989 Jun; 13(6 Pt 2):935-40. PubMed ID: 2737730
[TBL] [Abstract][Full Text] [Related]
16. Hypothalamic blood flow autoregulation remains unaltered following surgical and pharmacological blockade of central vasopressin.
Sandor P; Petty M; de Jong W; Palkovits M; de Wied D
Brain Res; 1991 Dec; 566(1-2):212-8. PubMed ID: 1814538
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
[TBL] [Abstract][Full Text] [Related]
18. Vasopressin analgesia: specificity of action and non-opioid effects.
Kordower JH; Bodnar RJ
Peptides; 1984; 5(4):747-56. PubMed ID: 6494025
[TBL] [Abstract][Full Text] [Related]
19. GABA agonists inhibit central sodium-induced vasopressin-dependent increases in arterial pressure.
Brennan TJ; Morris M; Haywood JR
Eur J Pharmacol; 1984 Aug; 103(3-4):223-34. PubMed ID: 6489442
[TBL] [Abstract][Full Text] [Related]
20. Area postrema lesions augment the pressor activity of centrally administered vasopressin.
Michelini LC; Barnes KL; Ferrario CM
Clin Exp Hypertens A; 1986; 8(7):1107-25. PubMed ID: 3769219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
